Back to discover
Disease
Trisomy
Late-stage therapeutic developmentEmerging research
2
Publications
7
Clinical trials
1
Related proteins
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Oncogene-like addiction to aneuploidy in human cancers.
Research2023-08-25Science (New York, N.Y.)
Research2002-06-01Nucleic acids research
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
- Q4 2027A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).
- Q4 2027A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase 2b Trial to Assess the Efficacy, Safety and Tolerability of AEF0217 for 24 Weeks in Adults and Older Adolescents With Down Syndrome.
Major developments
Upcoming trial readoutImportant
Results expected Q4 20272026-04-08
Upcoming trial readoutImportant
Results expected Q4 20272026-01-12
Clinical MilestonesViewHide
Results expected
- 2026-04-08A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase 2b Trial to Assess the Efficacy, Safety and Tolerability of AEF0217 for 24 Weeks in Adults and Older Adolescents With Down Syndrome.Results expected Q4 2027
- 2026-01-12A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).Results expected Q4 2027
Activity timeline2
- 2026-04-08ClinicalA Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase 2b Trial to Assess the Efficacy, Safety and Tolerability of AEF0217 for 24 Weeks in Adults and Older Adolescents With Down Syndrome.Results expected Q4 2027
- 2026-01-12ClinicalA Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).Results expected Q4 2027
Clinical trials
The current development programme across all trial phases.
Clinical programme
7
2
2
3
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20022023
Most influential
Major themes7
- Cell Cycle Proteins1
- DNA-Binding Proteins1
- Gene Editing1
- Neoplasms1
- Oncogenes1
- Trisomy1
- Tumor Suppressor Protein p531
Leading journals2
- Nucleic acids research1
- Science (New York, N.Y.)1
Leading researchers8
- Akalu SM1
- Brown LM1
- Diepvens F1
- Girish V1
- Hagenson RA1
- Kandikuppa PK1
- Lakhani AA1
- Lee SN1
Affiliations (unnormalised)6
- Cold Spring Harbor Laboratory1
- Columbia University School of Medicine1
- Department of Laboratory Medicine and Pathology1
- Howard Hughes Medical Institute1
- Johns Hopkins University School of Medicine1
- Yale University School of Medicine1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
The possession of a third chromosome of any one type in an otherwise diploid cell.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.